

# Leonie S Young

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4743200/publications.pdf>

Version: 2024-02-01

83  
papers

2,981  
citations

172457

29  
h-index

182427

51  
g-index

85  
all docs

85  
docs citations

85  
times ranked

4923  
citing authors

#	ARTICLE	IF	CITATIONS
1	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	5.0	320
2	The AIB1 Oncogene Promotes Breast Cancer Metastasis by Activation of PEA3-Mediated Matrix Metalloproteinase 2 (MMP2) and MMP9 Expression. <i>Molecular and Cellular Biology</i> , 2008, 28, 5937-5950.	2.3	169
3	Intrinsic Subtype Switching and Acquired <i>ERBB2</i> / <i>HER2</i> Amplifications and Mutations in Breast Cancer Brain Metastases. <i>JAMA Oncology</i> , 2017, 3, 666.	7.1	135
4	Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 2111-2122.	7.0	110
5	Differential Recruitment of Coregulator Proteins Steroid Receptor Coactivator-1 and Silencing Mediator for Retinoid and Thyroid Receptors to the Estrogen Receptor-Estrogen Response Element by $\hat{1}^2$ -Estradiol and 4-Hydroxytamoxifen in Human Breast Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 375-383.	3.6	92
6	Inverse relationship between ER- $\hat{1}^2$ and SRC-1 predicts outcome in endocrine-resistant breast cancer. <i>British Journal of Cancer</i> , 2004, 91, 1687-1693.	6.4	91
7	CD44 increases the efficiency of distant metastasis of breast cancer. <i>Oncotarget</i> , 2015, 6, 11465-11476.	1.8	89
8	The Function of Steroid Receptor Coactivator-1 in Normal Tissues and Cancer. <i>International Journal of Biological Sciences</i> , 2012, 8, 470-485.	6.4	82
9	Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. <i>Journal of the National Cancer Institute</i> , 2019, 111, 388-398.	6.3	81
10	Coassociation of Estrogen Receptor and p160 Proteins Predicts Resistance to Endocrine Treatment; SRC-1 is an Independent Predictor of Breast Cancer Recurrence. <i>Clinical Cancer Research</i> , 2009, 15, 2098-2106.	7.0	77
11	Growth factor-dependent regulation of survivin by c-myc in human breast cancer. <i>Journal of Molecular Endocrinology</i> , 2006, 37, 377-390.	2.5	76
12	Epigenetic Reprogramming of <i>HOXC10</i> in Endocrine-Resistant Breast Cancer. <i>Science Translational Medicine</i> , 2014, 6, 229ra41.	12.4	72
13	Metastatic Progression with Resistance to Aromatase Inhibitors Is Driven by the Steroid Receptor Coactivator SRC-1. <i>Cancer Research</i> , 2012, 72, 548-559.	0.9	65
14	Interaction of Developmental Transcription Factor HOXC11 with Steroid Receptor Coactivator SRC-1 Mediates Resistance to Endocrine Therapy in Breast Cancer. <i>Cancer Research</i> , 2010, 70, 1585-1594.	0.9	62
15	Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. <i>Oncogene</i> , 2008, 27, 3021-3031.	5.9	59
16	The LIM Domain Protein LPP Is a Coactivator for the ETS Domain Transcription Factor PEA3. <i>Molecular and Cellular Biology</i> , 2006, 26, 4529-4538.	2.3	57
17	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. <i>Cancer Research</i> , 2020, 80, 4314-4323.	0.9	51
18	Modulation of steroidogenic enzymes by orphan nuclear transcriptional regulation may control diverse production of cortisol and androgens in the human adrenal. <i>Journal of Endocrinology</i> , 2004, 181, 355-365.	2.6	49

#	ARTICLE	IF	CITATIONS
19	Nitric oxide in unilateral ureteral obstruction: Effect on regional renal blood flow. <i>Kidney International</i> , 2001, 59, 1059-1065.	5.2	48
20	NCOA1 Directly Targets <i>M-CSF1</i> Expression to Promote Breast Cancer Metastasis. <i>Cancer Research</i> , 2014, 74, 3477-3488.	0.9	48
21	Global Characterization of the SRC-1 Transcriptome Identifies ADAM22 as an ER-Independent Mediator of Endocrine-Resistant Breast Cancer. <i>Cancer Research</i> , 2012, 72, 220-229.	0.9	44
22	AIB1:ER $\beta$ Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor-Resistant Breast Cancer Cells. <i>Clinical Cancer Research</i> , 2012, 18, 3305-3315.	7.0	41
23	Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling. <i>Oncogene</i> , 2013, 32, 2799-2804.	5.9	39
24	Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. <i>Nature Communications</i> , 2022, 13, 514.	12.8	38
25	Identification and Characterization of Nucleolin as a COUP-TFII Coactivator of Retinoic Acid Receptor $\beta$ Transcription in Breast Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e38278.	2.5	37
26	Methods of renal blood flow measurement. <i>Urological Research</i> , 1996, 24, 149-160.	1.5	34
27	Cytosolic phospholipase A2 $\beta$ expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours. <i>British Journal of Cancer</i> , 2011, 104, 338-344.	6.4	34
28	Tamoxifen-induced ER $\beta$ -SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. <i>Endocrine-Related Cancer</i> , 2006, 13, 1135-1145.	3.1	32
29	Expression of the Breast Cancer Metastasis Suppressor Gene, BRMS1, in Human Breast Carcinoma: Lack of Correlation with Metastasis to Axillary Lymph Nodes. <i>Tumor Biology</i> , 2005, 26, 213-216.	1.8	31
30	A positive role for PEA3 in HER2-mediated breast tumour progression. <i>British Journal of Cancer</i> , 2006, 95, 1404-1409.	6.4	31
31	Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells. <i>Oncogene</i> , 2015, 34, 3871-3880.	5.9	31
32	Regional renal blood flow in normal and disease states. <i>Urological Research</i> , 1995, 23, 1-10.	1.5	30
33	Global Gene Repression by the Steroid Receptor Coactivator SRC-1 Promotes Oncogenesis. <i>Cancer Research</i> , 2014, 74, 2533-2544.	0.9	30
34	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. <i>Nature Medicine</i> , 2022, 28, 752-765.	30.7	30
35	Facilitating lifestyle changes to manage menopausal symptoms in women with breast cancer. <i>Menopause</i> , 2015, 22, 937-945.	2.0	28
36	The role of oestrogen receptor $\beta$ in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2. <i>Endocrine-Related Cancer</i> , 2010, 17, 255-264.	3.1	27

#	ARTICLE	IF	CITATIONS
37	Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients. <i>Endocrine-Related Cancer</i> , 2008, 15, 745-753.	3.1	26
38	COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2004, 91, 796-807.	2.6	25
39	Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 5371-5379.	7.0	25
40	Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings. <i>Breast Cancer Research</i> , 2018, 20, 140.	5.0	25
41	Superoxide radical and xanthine oxidoreductase activity in the human heart during cardiac operations. <i>Annals of Thoracic Surgery</i> , 1995, 60, 1289-1293.	1.3	24
42	Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2765-2777.	7.0	23
43	Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer. <i>Oncogene</i> , 2018, 37, 2008-2021.	5.9	23
44	RuvBl2 cooperates with Ets2 to transcriptionally regulate hTERT in colon cancer. <i>FEBS Letters</i> , 2011, 585, 2537-2544.	2.8	20
45	HOXC11 is a novel SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib. <i>British Journal of Cancer</i> , 2011, 105, 118-123.	6.4	20
46	Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 123.	5.0	20
47	S100 $\beta$ as a serum marker in endocrine resistant breast cancer. <i>BMC Medicine</i> , 2017, 15, 79.	5.5	20
48	FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. <i>Nature Protocols</i> , 2020, 15, 2503-2518.	12.0	20
49	Endothelin in Unilateral Ureteral Obstruction: Vascular and Cellular Effects. <i>Journal of Urology</i> , 2003, 169, 740-744.	0.4	19
50	Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1. <i>Breast Cancer Research</i> , 2006, 8, R33.	5.0	19
51	ADAM22 as a Prognostic and Therapeutic Drug Target in the Treatment of Endocrine-Resistant Breast Cancer. <i>Vitamins and Hormones</i> , 2013, 93, 307-321.	1.7	19
52	BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7139-7150.	7.0	18
53	Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF- $\kappa$ B. <i>Oncogene</i> , 2021, 40, 1077-1090.	5.9	18
54	CHANGES IN REGIONAL RENAL BLOOD FLOW AFTER UNILATERAL NEPHRECTOMY USING THE TECHNIQUES OF AUTORADIOGRAPHY AND MICROAUTORADIOGRAPHY. <i>Journal of Urology</i> , 1998, 160, 926-931.	0.4	16

#	ARTICLE	IF	CITATIONS
55	Cytoprotective effects of nitrates in a cellular model of hydronephrosis. <i>Kidney International</i> , 2002, 62, 70-77.	5.2	16
56	Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). <i>Breast Cancer Research and Treatment</i> , 2009, 117, 99-109.	2.5	14
57	Patient-Derived Xenografts of Breast Cancer. <i>Methods in Molecular Biology</i> , 2017, 1501, 327-336.	0.9	14
58	A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival. <i>Scientific Reports</i> , 2019, 9, 18518.	3.3	14
59	Raised plasma endostatin levels correlate inversely with breast cancer angiogenesis. <i>Journal of Surgical Research</i> , 2004, 116, 165-171.	1.6	13
60	Coregulatory protein's orphan nuclear receptor interactions in the human adrenal cortex. <i>Journal of Endocrinology</i> , 2005, 186, 33-42.	2.6	13
61	Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3692-3703.	7.0	13
62	FKBPL: a marker of good prognosis in breast cancer. <i>Oncotarget</i> , 2015, 6, 12209-12223.	1.8	13
63	Induction of Nitric Oxide Synthase is a Key Determinant of Progression to Pulmonary Injury in Experimental Pancreatitis. <i>Surgical Infections</i> , 2006, 7, 501-511.	1.4	12
64	A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. <i>EMBO Molecular Medicine</i> , 2022, 14, e14552.	6.9	12
65	An autoradiographic study of regional blood flow distribution in the rat kidney during ureteric obstruction- the role of vasoactive compounds. <i>BJU International</i> , 2001, 88, 268-272.	2.5	11
66	RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw111.	6.3	11
67	Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. <i>Cancers</i> , 2019, 11, 2005.	3.7	10
68	Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype. <i>Oncogene</i> , 2021, 40, 1318-1331.	5.9	10
69	Differential production of adrenal steroids by purified cells of the human adrenal cortex is relative rather than absolute. <i>European Journal of Endocrinology</i> , 2003, 148, 139-145.	3.7	9
70	Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers. <i>Journal of Molecular Medicine</i> , 2018, 96, 1025-1037.	3.9	9
71	Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1731-1743.	4.1	8
72	ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. <i>BMC Medicine</i> , 2020, 18, 349.	5.5	8

#	ARTICLE	IF	CITATIONS
73	Lapatinib: A competitor or companion to trastuzumab?. <i>Cancer Treatment Reviews</i> , 2009, 35, 574-581.	7.7	7
74	HER-2 Positive and p53 Negative Breast Cancers are Associated With Poor Prognosis. <i>Cancer Investigation</i> , 2011, 29, 365-369.	1.8	4
75	Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 3980-3989.	7.0	4
76	Nitric oxide in unilateral ureteral obstruction: Effect on regional renal blood flow. <i>Kidney International</i> , 2001, 59, 1059-1065.	5.2	4
77	Obstructive uropathy. <i>Current Opinion in Urology</i> , 1998, 8, 119-124.	1.8	2
78	Ligand-Independent Signalling Through Estrogen Receptor Pathways in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 115-144.	0.1	0
79	52. BrMPANEL: A PUBLIC RESOURCE OF ORGANOTROPIC CELL LINES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii10-ii11.	0.7	0
80	RADI-03. A strategy to personalize the use of radiation in patients with brain metastasis based on S100A9-mediated resistance. <i>Neuro-Oncology Advances</i> , 2021, 3, iii18-iii18.	0.7	0
81	Protein microarray identification of biomarkers in HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11575-e11575.	1.6	0
82	Impact of somatic PIK3CA and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 591-591.	1.6	0
83	The clinical impact of early immunological responses in human HER2-positive breast cancers on responsiveness to trastuzumab-based therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 587-587.	1.6	0